Affiliation:
1. Center for Health Services Research Uniformed Services University of the Health Sciences Bethesda Maryland USA
2. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Bethesda Maryland USA
3. Department of Orthopaedic Surgery and Center for Surgery and Public Health Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
Abstract
AbstractBackgroundDespite the known efficacy of colorectal cancer (CRC) screening, the rates of individuals undergoing such testing have remained lower than target thresholds, even prior to the healthcare disruptions associated with the COVID‐19 pandemic. We evaluated the impact of the COVID‐19 pandemic on CRC screening within a nationally representative US population and assessed disparities in screening across racial/ethnic groups and socioeconomic (SES) strata.MethodsWe performed a retrospective cross‐sectional study using all eligible TRICARE beneficiaries aged 45–64 years between FY 2018 and 2021. High‐risk individuals, those with a previous or current CRC diagnosis, and/or a personal/family history of colonic polyps, were excluded. The pre‐COVID‐19 period (September 1, 2018–March 31, 2020) was compared to the COVID‐19 period (April 1, 2020–September 30, 2021). Secondary analyses were performed, evaluating the interaction between the COVID‐19 time period, race, and our proxy for socioeconomic status.ResultsDuring the study period, we identified 1,749,688 eligible individuals. Following the onset of the COVID‐19 pandemic, CRC screening overall decreased from 34% in the pre‐pandemic period to 30% following the onset of the pandemic (p < 0.001). This finding persisted even after adjusting for confounders in multivariable analysis (odds ratio [OR] for the pandemic timeframe: 0.79; 95% CI: 0.27, 0.31; p < 0.001). In the setting of SES, in the pandemic period, the odds of individuals from both Senior Enlisted (OR: 0.55; 95% CI: 0.54, 0.56) and Junior Enlisted sponsor ranks (OR: 0.27; 95% CI: 0.25, 0.30) were diminished as compared to Senior Officers.Conclusions and RelevanceWe found a 21% reduction in the odds of CRC screening in the context of the COVID‐19 pandemic. Reductions in colonoscopies and other types of screening tests were not offset by changes in the use of at‐home tests such as Cologuard.
Funder
U.S. Department of Defense
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Reference28 articles.
1. American Cancer Society.Key statistics for colorectal cancer.2023. Accessed January 20 2023.https://www.cancer.org/cancer/colon‐rectal‐cancer/about/key‐statistics.html
2. National Cancer Institute.Cancer stat facts: colorectal cancer.2023. Accessed January 20 2023.https://seer.cancer.gov/statfacts/html/colorect.html
3. Centers for Disesae Control and Prevention.Health and economic benefits of colorectal cancer interventions.2022. Accessed January 20 2023.https://www.cdc.gov/chronicdisease/programs‐impact/pop/colorectal‐cancer.htm#:~:text=The%20High%20Cost%20of%20Colorectalof%20all%20cancer%20treatment%20costs.&text=The%20cost%20for%20medical%20services %240.6%20billion%20for%20prescription%20drugs
4. Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic
5. Changes in Cancer Screening in the US During the COVID-19 Pandemic
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献